Need Assistance?

US & Canada:
+
UK: +

Our Highlights

GMP Grade Efficient workshop for GMP production.
Optimal Prices Buying products on this site guarantees the best price!
Commercial Batches Independent GMP manufacturing suites that handle commercial batches
Prompt Delivery Warehouses in multiple cities to ensure timely delivery
Flexible Quantity Quantities available from milligrams to ton

L-Leucine amide hydrochloride

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

L-Leucinamide Hydrochloride, is a derivative of Leucine, which is an essential amino acid, and acts as a nutrient signal to stimulate protein synthesis. L-Leucinamide Hydrochloride, is shown to be the potential elicitor of insulin secretion in rats.

Category

L-Amino Acids

Catalog number

BAT-003992

CAS number

10466-61-2

Molecular Formula

C6H14N2O·HCl

Molecular Weight

166.70

Specification
Reference Reading

IUPAC Name

(2S)-2-amino-4-methylpentanamide;hydrochloride

Synonyms

L-Leu-NH2 HCl; [(2S)-1-amino-4-methyl-1-oxopentan-2-yl]azanium; (R)-2-Amino-4-Methylvaleramide; L-Leucinamide Hydrochloride

Appearance

White powder

Purity

≥ 99% (HPLC)

Density

0.98 g/cm3

Melting Point

254-256 °C

Boiling Point

250.9 °C at 760 mmHg

Storage

Store at 2-8 °C

InChI

InChI=1S/C6H14N2O.ClH/c1-4(2)3-5(7)6(8)9;/h4-5H,3,7H2,1-2H3,(H2,8,9);1H/t5-;/m0./s1

InChI Key

VSPSRRBIXFUMOU-JEDNCBNOSA-N

Canonical SMILES

CC(C)CC(C(=O)N)N.Cl

1.Oral delivery of a renin inhibitor compound using emulsion formulations.

Kararli TT1, Needham TE, Griffin M, Schoenhard G, Ferro LJ, Alcorn L. Pharm Res. 1992 Jul;9(7):888-93.

The oral delivery of O-(N-morpholino-carbonyl-3-L-phenylaspartyl-L- leucinamide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylhetane (I), a new renin inhibitor, was studied in the in vivo rat model using emulsion formulations. The components of the emulsion formulations were chosen based on their proposed effects on membrane structure, membrane fluidity, and solute transport. The percent absolute bioavailability (%AB) of I was increased from 0.3% (water suspension) to 5.1% when long-chain unsaturated fatty acid (oleic acid, linoleic acid, etc.)- and mono- and diglyceride (monolein, dilaurin, etc.)-containing emulsion formulations were used. Considering very high first-pass liver extraction of the compound (80%), it is suggested that emulsion formulations increased the intestinal transport of the compound significantly. The solubility of I in aqueous media with and without bile salt (20 mM) was found to be low (approximately 1 micrograms/ml).